US20090104213A1

US20090104213A1 - Vaccine for House Dust Mite Allergen Using Naked DNA

Info

Publication number: US20090104213A1
Application number: US12/204,425
Authority: US
Inventors: Tai June Yoo
Original assignee: Individual
Current assignee: Individual
Priority date: 1999-02-25
Filing date: 2008-09-04
Publication date: 2009-04-23
Also published as: WO2000050455A3; WO2000050044A1; WO2000050455A2; EP1162983A1; AU3605100A; AU3605300A; CA2362928A1; KR20020000218A; US7439233B1

Abstract

Vaccination with the DNA encoding T-cell epitopes to the house dust mite Dermatophagoides pteronyssimus (Der p) and Dermatophagoides farinae (Der f were effective in the inhibition of the allergen induced IgE synthesis. Gene therapy using T-cell epitope encoding DNA is useful in combating allergic disease.

Description

CROSS REFERENCE TO RELATED APPLICATION

The present application is a Continuation application of U.S. Nonprovisional patent application Ser. No. 09/513,645, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/121,547 filed Feb. 25, 1999, which are incorporated by reference in their entirety herein.

FIELD OF THE INVENTION

The present invention relates to a method of vaccination using naked DNA encoding T-cell epitopes, such as those of the house dust mite Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f), which results in the suppression of IgE production. The present invention also relates to novel combinations of mixed plasmid DNA useful in IgE suppression.

BACKGROUND OF THE INVENTION

Genetic vaccination with naked plasmid DNA provides a long standing cellular and humoral immune response and promotes a shift in the pattern of cytokines produced by the T-cells. Peptides derived from T-cell epitopes can downregulate cytokine production and prevent specific antibody formation and administration of a single dominant epitope may tolerize the response to all the T-cell determinants within that protein.
About 15% of the world population exhibit a hypersensitivity response to common aeroallergens resulting in asthma, eczema, and rhinitis. The most frequently implicated allergens are derived from the house dust mite (HDM) including Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f). From the serological analysis of IgE antibodies from HDM-allergic individuals, a major component (>90%) had a humoral response that was reactive with the group 1 and group 2 allergen. Therefore, using truncated recombinant proteins and overlapping peptides based on the nucleotide sequences, it is possible to generate T-cell epitope maps for human responses to HDM-derived allergens and to allow the development of immunotherapy. However, vaccines using peptides has a substantial limitation that in the peptides are poor immunogens. Recently, studies have shown it has revealed that genetic vaccinations with naked DNA provide long-lasting cellular and humoral immune responses.
Long-term persistence of plasmid DNA and foreign gene expression in muscle suggested that muscle is an attractive target tissue for gene vaccination. Many studies have revealed that gene immunization with plasmid DNA encoding whole allergens or protein antigens induced strong T helper type (Th1) immune responses in mice and rats.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides a method of vaccination using naked DNA encoding T-cell epitopes, such as those of the house dust mite Dermatophagoides pteronyssinus (Der p) and Dermatophagoides farinae (Der f) which results in the suppression of IgE production. The present invention also provides novel combinations of mixed plasmid DNA useful in IgE suppression.
The invention also includes a composition for reducing IgE production, comprising: a pharmacologically acceptable medium and a substantially pure, immunogenic plasmid DNA encoding a T-cell eptitope. The present invention provides a method of reducing IgE production, comprising administering a composition comprising a pharmacologically acceptable medium and a substantially pure, immunogenic plasmid DNA encoding a T-cell eptitope. The present invention also provides a vaccine for reducing the severity of an allergic disease in a mammal, comprising a pharmaceutically acceptable carrier and at least one plasmid DNA that encodes a T-cell epitope from a house dust mite antigen wherein the dust mite is selected from the group consisting of the house dust mite Dermatophagoides pteronyssinus (Der p), Dermatophagoides farinae (Der f) and mixtures thereof. The present invention further provides a composition for reducing IgE production, comprising: a pharmacologically acceptable medium and a substantially pure, immunogenic plasmid DNA encoding a major HDM allergen selected from the group consisting of Der p 1, Der p 2, Der p 3, Der f 1, Der f 2, Der f3 and mixtures thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

The various features and advantages of the invention will be apparent from the attached drawings, in which like reference characters designate the same or similar parts throughout the figures, and in which:

FIGS. 1A-G are graphs showing the serum levels in mice versus number of weeks after immunization. FIG. 1B is a graph showing the Der p specific anti-IgE serum levels in mice versus number of weeks after immunization. FIG. 1C is a graph showing the Der p specific anti-IgG2a serum levels in mice versus number of weeks after immunization. FIG. 1D is a graph showing the Der p specific anti-IgG serum levels in mice versus number of weeks after immunization.

FIG. 1E is a graph showing the Der p specific anti-IgG1 serum levels in mice versus number of weeks after immunization. FIG. 1F is a graph showing the IFN-γ serum levels in mice versus number of weeks after immunization. FIG. 1G is a graph showing the IL-4 serum levels in mice versus number of weeks after immunization. FIG. 1H is a graph showing cell proliferation versus concentration of Der p.

FIG. 2A is a graph showing Der p specific IgE serum levels in mice versus number of weeks after immunization. FIG. 2B is a graph showing the Der p specific IgG2a serum levels in mice versus number of weeks after immunization. FIG. 2C is a graph showing the Der p specific IgG1 serum levels in mice versus number of weeks after immunization. FIG. 2D is a graph showing the Der p specific anti-IgG serum levels in mice versus number of weeks after immunization. FIG. 2E is an autoradiograph showing the levels of mRNA expression in control and vaccinated mice. FIG. 2F is a graph showing the total IgE serum level in mice after intramuscular injection versus weeks after immunization.

FIGS. 3A-C are graphs showing antibody levels in mice versus weeks after immunization where the antibody measure is (A) total IgE, (B) HDM-specific IgE, or (C) HDM-specific IgG.

FIGS. 4A-C are photomicrographs of lung tissue from control or vaccinated mice where the samples are (A) lung from a control mouse (×100), (B) lung from control mouse (×200), (C) lung from vaccination mouse (×200), and (D) bronchial wall from control mouse (×600).

FIGS. 5A-E are photomicrographs of lung tissue from control or vaccinated mice stained for CD8+ T cells where the samples are (A) lung from a control mouse (×100), (B) lung from control mouse (×200), (C) lung from vaccination mouse (×200), and (D) bronchial wall from control mouse (×600).

The present invention will be further described in connection with the following Examples, which are set forth for purposes of illustration only. Parts and percentages appearing in such Examples are by weight unless otherwise stipulated.

EXAMPLES

Example 1

Human Epitope Vaccination

Introduction
To determine whether the vaccination with naked plasmid DNA encoding only a T-cells epitope peptide is able to suppress the allergic reaction in vivo, the mixed naked DNA plasmids encoding the five classes of human T-cell epitopes on Der p 1 and Der p 2 were used for genetic vaccination of BALB/c mice. The control mice were injected with the pcDNA 3.1 blank vector. There was a reduction in the total and Der p-specific immunoglobulin E (IgE) synthesis in the vaccinated mice compared with the control mice. In the Der p specific-IgG2a antibody response, the vaccinated mice showed more prominent responses than the control mice. Also analysis of the cytokines serum levels after immunization of Der p extract revealed that in the vaccinated mice there was an elevation in the level of interferon-γ, a Th1 cytokine associated with suppression of IgE production. The histologic studies showed that there was much less infiltration of inflammatory cells observed in lung tissue of the vaccinated mice than that of the control mice.
To evaluate whether the vaccination with naked plasmid DNA coding only a T-cell epitope peptide suppresses allergic reactions as effectively as the vaccination with DNA encoding whole allergen, an immune response to gene immunization with plasmid DNA encoding major T-cell epitopes in Der p 1 and 2 to challenges with whole Der p extract in mice to mimic realistic clinical setting was investigated. It was demonstrated that genetic vaccination indeed induced strong Th1 immune responses which reduced the IgE antibody production and allergic responses against Der p. Therefore, it would be ideal to develop an alternate naked DNA vaccination method which could be even safer than injecting whole segments of the allergen encoding region of either Der p 1 or Der p2.
Materials and Methods
Mice
20 BALB/c mice at the age of 6-8 weeks were purchased from Jackson Laboratory (Bar Harbor, Me.) and bred at the University of Tennessee (Memphis, Tenn.). This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animal Welfare Act (7 U.S.C. et seq.); the animal use protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Tennessee.
Plasmid Construction
Total mRNA was isolated from Der p and Der f HDM, respectively. By using murine leukemia virus reverse transcriptase and random hexanucleotide primer following the instructions of the Perkin Elmer Gene Amp RNA PCR kit (Perkin Elmer, Branchberg, N.J.), first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR. The cDNA was used in PCR with Taq polymerase and with primers specific for human T-cell epitopes of Der p 1 and 2. These primers, which cover the mature excreted region of each genes and include EcoR1 and Xba1 sites for cloning, summarized in Table 1. The amplified PCR products were subcloned into pcDNA3.1 eukaryotic expression vector (Invitrogen, San Diego, Calif.) and then sequenced.
DNA Preparation and Vaccination
Each plasmid construct was prepared using Maxi prep (Qiagen, Chatsworth, Calif.). Mice were vaccinated by injection with 300 μg of pcDNA3.1 blank vector in 100 μl of PBS (control mice) or with 300 mg of the mixed naked DNA encoding the human T-cell epitopes of Der P 1 and 2 in 100 μl of PBS (vaccination mice) three times at weekly intervals into muscle.
Immunization and Inhalation of Allergen to Mice
The Der p-induced sensitivity in a mouse model was performed as described. Der p was emulsified with an equal volume of complete Freund's adjuvant (CFA) for immunization. Three weeks after last vaccination, mice were sensitized by injecting subcutaneously at the base of the tail with 100 μg of Der p extract in CFA. The mice were also given an intraperitoneal dose of 300 ng of purified pertussis toxin at 24 and 72 hours after first immunization. Seven days later, the mice were boosted again with the same amount of antigen in incomplete Freund's adjuvant. Mice received intranasally by inhalation intranasal with 10 μg of Der p extract six times at weekly intervals from boost.
Determination of Total and Der P-Specific IgE
The bloods from the 7 mice in two groups were collected three times on week 0 (first immunization), 3, and 6. The total IgE level was determined by ELISA as follows. One hundred microliters of anti-mouse IgE capture mAb (clone R35-72; Pharmingen, San Diego, Calif.) were added in each well to plate and incubated overnight at 4° C. After washing, two hundred microliters of 10% fetal calf serum were incubated at room temperature for 30 min. The plates were washed five times with washing buffer and incubated with the diluted mouse serum overnight at 4° C., followed by the addition of one hundred microliters of HRP-conjugated anti-mouse IgE detection mAb (clone R35-118; Pharmingen, San Diego, Calif.) overnight at 4° C. The plates were washed five times before adding citric acid-phosphate buffer (pH 5.0) containing 0.15 mg/ml of O-phenylenediamine (Sigma, St. Louis, Mo.). The color was developed at room temperature, and the reaction was stopped by 2.5 M sulfuric acid. The color was measured at 492 nm (Bio-Rad, Richmond, Calif.). The purified mouse anti-IgE antibody (Pharmigen, San Diego, Calif.) was used for total IgE standard. In the measure of the Der p specific IgE, the plate were coated with 25 μg/ml of Der p in 0.1 M carbonate buffer (pH 9.6) and serum samples were diluted fivefold in 10% FCS. The other procedures were the same as the measurement of Der p-specific IgE. The levels of Der p-specific IgE were referenced to the standard serum pooled from six mice that were immunized with 100 μg of Der p twice and inhaled with 10 μg of antigen six times. The standard serum was calculated as 100 ELISA units/ml.
Determination of Der p specific IgG, IgG1, and IgG2a
The Der P specific IgG, IgG1, and IgG2a were determined by ELISA as follows. Purified antigens (5 μg/ml) were coated onto the assay plate and incubated overnight at 4° C. The other procedures were the same as the measurement of Der p-specific IgE.
Cytokines serum levels in BALB/c mice after immunization with Der p Blood samples from the 7 mice in two groups were collected two times on week 0 (first immunization), and 2 weeks. The levels of IFN-γ and IL-4 were measured using the antibody pairs purchased from PharMingen, according to the manufacturer's instructions.
Histological Examination of Lung Tissue
Mice were anesthetized with a mixture of ketalar (35 mg/ml), rompun (0.6%/ml) and atropine (0.1 mg/ml), of which 0.2 ml was injected intramuscularly. The vascular bed of the lungs was perfused with 0.01 M Phosphate-buffered saline (PBS) and then with 4% paraformaldehyde 0.1 M PBS buffers. Whole lungs were taken out and were stored in 4% paraformaldehyde for 24 h at 4° C. After fixation, these tissues were dehydrated and embedded in paraffin. Frozen sections are cut at 6 μm in thickness were stained by hematoxylin and eosin. After coding, the sections were evaluated by two observers using light microscopy. The amount of mononuclear cells per section was scored using the method described by Hessel et al. This scoring method discriminates between the presence of mononuclear cells around blood vessels (score 0-3), and around bronchioli (score 0-3), and the number of patchy cellular infiltrates (score 0-3). Histological scores were analyzed using non-parametric Mann-Whitney U test. At least five mice were examined.
Lymph Node Cell Proliferation
The proliferation assay was performed as described. Briefly, 10 days after immunization, lymph nodes were removed aseptically, and single-cell suspension was prepared. The cells (2×10⁵cells per well) were cultured with the serial dilution of Der p (range, 0.01-10 g/ml). Cultures were set up in 200 μl RPMI1640 supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, Utah), 1 mmol/L sodium pyruvate, 100 μg/ml penicillin, 100 μg/ml streptomycin, 2 mmol/L glutamine, 5×10⁻⁵mol/L 2-mercaptoethanol, 20 mmol/L HEPES (pH 7.4), and 50× nonessential amino acids. After 72 hours culture, 1 μCi of [³H]thymidine (Du Pont, Wilmington, Del.) was added to each well. Eighteen hours later, cells were harvested, and measured by liquid scintillation counting. Values were expressed in counts per minute as follows: Counts per minute with antigen-Counts per minute without antigen. Each sample was run in triplicate. RPMI medium 1640, sodium pyruvate, penicillin, streptomycin, glutamine, HEPES, and 50× nonessential amino acids were purchased from Irvine Scientific (Santa Ana, Calif.), and 2-mercaptoethanol was purchased from Sigma Chemical Co. (St. Louis, Mo.).
Statistical Analysis
The immunoglobulin response data was analyzed by Student's paired t test for comparisons between control and experimental mice. Histological grades were analyzed using a non-parametric Mann-Whitney U test. Data was expressed as mean±SD. A P value<0.05 was considered significant.
Results
Suppression of total and Der p-specific IgE antibody production by gene vaccination.
To determine the effect of vaccination with DNA encoding T-cell epitopes, we examined total and Der p specific IgE antibody levels by ELISA (FIGS. 1A and 1B). The gene vaccination with the human T cell epitopes of Der p 1 and 2 showed about 50% inhibition of Der p-specific IgE and more than 50% inhibition of total IgE as compared with the control mice at week 6. Thus, genetic vaccination could inhibit an in vivo allergen-specific IgE synthesis efficiently. To study the effects of DNA vaccination on B cell immunity, we measured Der p specific serum antibodies. The increase in production of Der p-specific IgG2a antibodies in the vaccination mice was greater than that in the control mice after 3 weeks although Der p specific IgG responses were similar between the two groups (FIGS. 1C and 1D), But in the Der p-specific IgG1 response, control mice showed more prominent production than vaccination mice (FIG. 1E).
IFN-γ and IL-4 serum levels in BALB/c mice after immunization with Der p extract
To determine whether the Th1 or Th2 cytokines were produced in response to genetic vaccination with the human T-cell epitope genes, we measured IL-4 and IFN-γ serum levels. The IFN-γ serum level in vaccination mice (648.29±166.78 pg/ml) was observed to be higher than in control mice (undetectable) at 2 weeks after immunization of Der p extract (See FIG. 1F). In parallel, the IL-4 serum levels were detected contrary to the result of IFN-γ (control mice 23.63±3.66 pg/ml versus vaccination mice undetectable) (see FIG. 1G). Our results suggested that the genetic immunization with the plasmid DNA encoding T-cell epitopes might also induce a Th2 to Th1 cytokine shift.
Lymph Node Cells Proliferation
To determine whether the protective effect of gene vaccination was due to the deletion of T-cells or the induction of unresponsiveness, we examined lymph node cell proliferation in response to different concentrations of Der p. As seen in FIG. 1H, lymph node cells from the vaccinated mice showed a linear stimulation when concentration of Der p ranged from 0.01 μg/ml to 10 μg/ml, as did the lymph node cells from the control mice.
Histological Examination of Lung Tissue
To examine whether the genetic vaccination affected cellular response of lung or not, we stained the lung at the end of the experiment by histological method. The lung from the control mice showed an increase in the number of mononuclear cells infiltrates around bronchioli (mean number 1.5667±0.89 respectively, versus 0.5333±0.6756 in vaccination mice), and around blood vessels (mean number 0.8833±0.8847 respectively, versus 0.3833±0.6662 in vaccination mice) in comparison to the number of mononuclear cell infiltrates in the vaccination mice. Also control mice observed had significantly more patch cellular infiltrates than vaccination mice (mean number 1.3±1.0939 respectively, versus 0.35±0.6331 in vaccination mice).
Discussion
Diseases such as allergic asthma, rhinitis, and atopic dermatitis are all characterized by elevated levels of serum IgE. Total and specific IgE positivity also showed a close relationship with clinical symptoms in atopic allergy. Analysis of antigen specificity of T-cell clones reactive with Der p 1 and Der p 2, with truncated recombinant proteins and synthetic peptides, has allowed several sites of T-cell recognition to be identified at different locations within Der p 1 and Der p 2. Several laboratories are now investigating the development of a new generation of immunotherapeutic strategies based on the modulation of T-cell function. Immunotherapy treatment has proven to be effective in treating some forms of allergy, but the antigen used was a poor immunogen and was needed at a higher concentration than the amount derived intracelluarly from processed antigens. Recently gene immunization with naked DNA was shown to suppress induction of IgE synthesis. These data suggest that immunization with a plasmid DNA (Pdna) containing the gene for the minor HDM allergen Der p 5 may induce Th1 immune responses to the encoded antigens. The Der p 5 allergen reacts with about 40% of allergic sera but the Der p 1 and 2 allergens react with about 80% of allergic sera.^19,20It was examined whether plasmid DNA encoding T-cell epitopes of human Der p 1 and Der p 2 would also be able to induce abrogation of allergic responses in mice when they are given the naked DNA vaccine. We have analyzed the effects of gene vaccination with a plasmid encoding T-cell epitopes of Der p 1 (residues 45-67, and 94-143) and Der p 2 (residues 11-40, 61-104, and 111-129). Our results showed greater than 50% inhibition of total IgE and Der p-specific IgE at the end of the study (FIGS. 1A and 1B). Thus, this result suggested that gene vaccination with plasmid DNA encoding the T-cell epitopes could also suppress induction of IgE synthesis.
To determine whether the suppressive effect of gene vaccination was due to the deletion of T-cells or the induction of unresponsiveness, we examined lymph node cell proliferation in response to different concentrations of Der p. We found that lymph node cells taken from BALB/c mice were able to respond by proliferation depending on the Der p concentration, with a similar pattern to that of the cells taken from the control mice. T-cell deletion has mainly been observed after administration of high doses of antigen or peptide. Furthermore, numerous experimental systems have shown that presentation of antigen by nonprofessional antigen presenting cells (APCs) that lack co-stimulatory capacity results in anergy rather than priming.²³But professional APCs, Langerhans cells or macrophages, may act as APCS for intramuscular DNA vaccination. Also our results demonstrate strong T-cell responses to varying concentrations of Der p. Thus, gene vaccination did not induce T-cell deletion or anergy. The T helper 2 (Th2) cells mainly produce IL-4, IL-S and IL-10 which induce antibody production in B cells, including above all, the formation of IgE which plays a central role in allergic responses. IFN-γ is the Th1 cytokine responsible for the inhibition of IL-4-mediated IgE responses and promotes the formation of IgG2a. Protein immunization induces a Th2 response, as shown by IgG1 and IgE antibody formation and IL-4 and IL-5-secreting T-cells. In contrast, gene immunization with plasmid DNA induces a Th1 response with IgG2a antibody production and IFN-γ secreting T-cell. To study the immune mechanisms involved in suppression of IgE synthesis after DNA vaccination, we measured the IFN-γ and IL-4 serum levels in BALB/c mice after immunization of Der p extract. In the vaccinated mice there was an elevation in the Th1 cytokine IFN-γ associated with suppression of IgE synthesis. In parallel, there was a reduction in the Th2 cytokine IL-4. Lee et al reported that the Th1 response dominated over the Th2 response and downregulated preexisting IgE antibody formation after genetic immunization. Our results showed that the genetic immunization with the plasmid DNA encoding only T-cell epitopes might also induce a Th2 to Th1 cytokine shift.
To study the effects of DNA vaccination on B cell immunity, we measured Der p specific serum antibodies. At 6 weeks after immunization, total serum levels of IgG2a Der p specific antibody increased and the Der p specific IgG1 response was reduced in the vaccination mice compared with control mice although the Der p specific IgG responses were similar between the two groups. IgG2a is dependent on interferon-γ (IFN-γ) as an IgM-to-IgG2a switch factor and is believed to be typical for a Th1 response. In contrast, IgG1 depends on IL-4 secreted by Th2 cells.²⁸The Der p specific IgG isotype data further indicated that genetic vaccination with DNA encoding the T-cell epitopes induces a Th2 to Th1 cytokene shift, since vaccination group had increased 1g-2a levels compared with the levels of the control group. Our results suggested that genetic immunization might suppress IgE production by inducing a Th2 to Th1 cytokine shift.
Allergic asthma is characterized as a chronic inflammatory disease of the bronchi and it is well established that a variety of cells including mast cells, eosionphils and lymphocytes play a role in this process. After inhalation challenge, the inflammatory cells migrate from the peripheral blood to the site of inflammation in the bronchial mucosa and bronchoalveolar fluid shows dominant Th2-type cytokines. Our histological evaluation revealed that a significant number of patch mononuclear cell infiltrates were observed around the bronchioles and blood vessels in the vaccination mice compared with the control mice. T lymphocytes have been suggested to play a key role in orchestrating the interaction of the participating cells since they are able to release an array of cytokines which can attract, prime and activate other cell types. A successful outcome of immunotherapy has been associated with the development of suppressor T-cells, which can downregulate the allergic response. It has been suggested that the change in the function of T-cells might cause a reduction in the number of inflammatory cells infiltrating lung tissue. This data indicated that gene immunization affects not only humoral immune responses but also cellular responses.
The vaccination with mixed naked DNA encoding only T-cell epitopes might induce abrogation of allergic response in mice as effectively as DNA encoding whole segment allergen. Thus gene therapy using DNA encoding T-cell epitopes could be an ideal way of combating allergic disease in the future.

TABLE 1

Sequence of Primers for Human T-cell epitopes of Der p 1 and 2.

Der p 1 ephope (residues 45-67)	5′-CCG GAA TTC GCC GCC ACC ATG TCA GCT TAT
	TTG GCT TAC CGT-3′
	[SEQ.ID.NO: 45]
	5′-TGC TCT AGA TTG G AA GCA CAA TCG ACT AAT
	TCT-3′
	[SEQ.ID.NO: 46]

Der p 1 epitope (residue 94-143)	5′-CCG GAA TTC GCC GCC ACC ATG TAT CGA TAC
	GTT GCA CGA GAA-3′
	[SEQID.NO: 47]
	5′-TGCTCT AGA TTG CCA ATA ATGACG GCA AT-3′
	[SEQ.ID.NO: 48]

Der p 2 epitope (residue 11-40)	5′ CCG GAA TTC GCC GCC ACC ATG CAT GAA
	ATC AAA AAA AGT TTT GGT A-3′
	[SEQ.ID NO: 49]
	5′-TGC TCT AGA TTA ACG GCT TCA ATT GGA
	ATT CT-3′
	[SEQ.ID.NO: 50]

Der p 2 epitope (residue 61-104)	5′-CCG GAA TTC GCC GCC ACC ATG TTA GAA GTT
	GAT GTTCCCGGT-3′
	[SEQ.ID.NO: 51]
	5′-TGC TCT AGA TTA ACA TTT TCA GAT TTT GGT-3′
	[SEQ.ID.NO: 52]

Der p 2 epitope (residue 111-129)	5′-CCG GAA TTC GCC GCC ACC ATG GGT GAT GAT
	GGT GTT TGG CCT-3′
	[SEQ.ID.NO: 53]
	5′-TGC TCT AGA TTA ATC GCG GAT TTT AGC ATG
	AGT AGC-3′
	[SEQ.ID.NO: 54]

TABLE 2

Inflammatory cells in the lung tissue
after immunization with Der p.

	Around	Around	Patch cellular
Group	bronchioli	blood vessels	infiltrates

Control	1.5667 ± 0.89	0.8833 ± 0.8847	1.3 ± 1.0939
Vaccination	0.5333 ± 0.6756*	0.3833 ± 0.6662*	0.35 ± 0.6331*

*P < 0.05 compared with the control group

Example 2

The Effect of Vaccination with DNA Encoding Murine T-Cell Epitopes on

Der p

1 and 2 Induced Immunoglobulin E Synthesis

We would like to examine the effect of vaccination with DNA encoding only the murine T-cell epitopes on the IgE production. Our results suggested that genetic vaccination indeed induced the Th1 cytokine immune responses which in turn reduced the IgE antibody production and allergic responses against Der p. Therefore it would be ideal to develop an alternative naked DNA vaccination method which could be even safer than injecting whole segments of the encoding region of Der p 1 or Der p2.
Materials and Methods
Mice
20 BALB/c mice at the age of 6-8 weeks were purchased from Jackson Laboratory (Bar Harbor, Me.) and bred at the University of Tennessee (Memphis, Tenn.). This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animal Welfare Act (7 U.S.C. et seq.); the animal use protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Tennessee.
Plasmid Construction
Total mRNA was isolated from Der p and Der f HDM, respectively. By using murine leukemia virus reverse transcriptase and a random hexanucleotide primer following the instructions of the Perkin Elmer Gene Amp RNA PCR kit (Perkin Elmer, Branchberg, N.J.), first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR. The cDNA was used in PCR with Taq polymerase and primers specific for Der p 1 and 2 epitopes. These primers, which cover the mature excreted region of each genes and include EcoR1 and Xba1 sites for cloning are summarized in Table 3. The amplified PCR products were subcloned into pcDNA3.1 eukaryotic expression vector (Invitrogen, San Diego, Calif.) and then sequenced.
DNA Preparation and Vaccination
Each plasmid construct was prepared using Maxi prep (Qiagen, Chatsworth, Calif.). Mice were vaccinated by injection with 300 μg of pcDNA3.1 blank vector in 100 μl of PBS (control group) or with 300 mg of the mixed naked DNA encoding the murine T-cell epitopes of Der p 1 and 2 (vaccination group) three times at weekly intervals into muscle.
Immunization and Inhalation of Allergen to Mice
The Der p-induced sensitivity in a mouse model was performed as described. Der p was emulsified with an equal volume of complete Freund's adjuvant (CFA) for immunization. Three weeks after the last vaccination, mice were sensitized subcutaneously at the base of the tail with 100 μg of Der p extract in CFA. The mice were also given an intraperitoneal dose of 300 ng of purified pertussis toxin at 24 and 72 hours after first immunization. Seven days later, the mice were boosted again with the same amount of antigen in incomplete Freund's adjuvant. 10 μg of Der p extract was administered intranasally to the mice six times at weekly intervals from boost.
Determination of Der p Specific IgG1, IgG2a, and IgE
Blood from the 6 mice in two groups was collected six times on week 0 (first immunization), 3, and 6. The Der p specific IgG, IgG1, and IgG2a levels were determined by ELISA as follows. Fifty microliters of Der p (5 μg/ml in 0.1 M carbonate buffer, pH 9.6) were dispensed in each well of a polystyrene microtiter plate (Cost, Cambridge, Mass.) and incubated overnight at 4° C. The antigen-coated plates were washed three times in 0.05% PBS-Tween 20 buffer (washing buffer) and incubated with mice sera overnight at 4° C. The plates were washed five times with washing buffer and incubated with peroxidase conjugated anti-mouse IgG, IgG1 and IgG2a antibodies (Sigma, St. Louis, Mo.) overnight at 4° C. The plates were washed five times before adding citric acid-phosphate buffer (pH 5.0) containing 0.15 mg/ml of O-phenylenediamine (Sigma, St. Louis, Mo.). The color was developed at room temperature, and the reaction was stopped by 2.5 M sulfuric acid. The color was measured at 492 nm (Bio-Rad, Richmond, Calif.). In order to measure the Der p specific IgE, the plate were coated with 25 μg/ml HDM in 0.1 M carbonate buffer (pH 9.6) and serum samples were diluted fivefold in 100% FCS. The other procedures were the same as the measurement of Der p-specific IgG except HRP-conjugated anti-mouse IgE detection mAb (clone R35-118; Pharmingen, San Diego, Calif.). The level of Der p-specific IgE were referenced to the standard serum pooled from six mice that were immunized with 100 μg of HDM twice and inhaled 10 μg of antigen six times. The standard serum was calculated as 100 ELISA units/ml.
Histological Examination of Lung Tissue
Mice were anesthetized with a mixture of ketalar (35 mg/ml), rompun (0.6%/ml) and atropine (0.1 mg/ml), of which 0.2 ml was injected intramuscularly. The vascular bed of the lungs was perfused with 0.01 M Phosphate-buffered saline (PBS) and then with 4% paraformaldehyde 0.1 M PBS buffers. Whole lungs were taken out and were stored in 4% paraformaldehyde for 24 h at 4° C. After fixation, these tissues were dehydrated and embedded in paraffin. Frozen sections cut at 5 μm in thickness were stained by hematoxylin and eosin. After coding, the sections were evaluated by two observers using light microscopy. The amount of mononuclear cells per section was scored using the method described by Hessel et al. This scoring method discriminates between the presence of mononuclear cells around blood vessels (score 0-3), around bronchioli (score 0-3), and the number of patchy cellular infiltrates (score 0-3). Histological scores were analyzed using non-parametric Mann-Whitney U test. At least five mice were examined.
Immunohistochemical Staining for CD4+ and CD8+ T-Cells in Lung.
The lung tissues from the experimental and control group mice were removed after the final intranasal inhalation. The tissues were fixed with periodat-lysine-paraformaldehyde solution for 24 h at 4° C. Frozen sections cut at 4 to 6 μm in thickness were rehydrated and rinsed in cold PBS. The endogenous pseudoperoxidase was blocked with absolute methanol containing 0.5% hydrogen peroxide for 20 min at room temperature. The sections were treated with 10% normal goat serum in PBS to reduce the nonspecific binding. Biotin conjugated rat anti-mouse CD8 or CD4 monoclonal antibody (Pharmingen, San Diego, Calif.), diluted to 1:200 in PBS containing 0.5% bovine serum albumin, was applied to the sections and incubated overnight at 4° C. After rinsing, the sections were incubated with avidin-biotin peroxidase complexes (Vectastain Elite ABC Kit, Vector Laboratories Inc., Burlingame, Calif.) for 30 min at room temperature and rinsed sufficiently with PBS. The reaction was developed with 0.02% 3,3′-diaminobenzidine in 0.05 M of Tris buffer (pH 7.6) with 0.005% hydrogen peroxide for 7 min. The sections were dehydrated, cleared in xylene, and mounted.
Measuring Cytokine mRNA Expression
Mice from two groups were sacrificed 10 days after immunization with Der p extract. The lymph nodes were removed from mice and stimulated with recombinant Der p (100 μg/ml) in vitro for IS hrs. The cells were washed with PBS buffer and mRNAs prepared (Biotecx, Houston, Tex.). By using murine leukemia virus reverse transcriptase and random hexanucleotide primers following the instructions of the Perkin Elmer Gene Amp RNA PCR kit (Perkin Elmer, Branchberg, N.J.), first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR analysis. To determine the relative abundance of each cytokine mRNA expression, the amount of each cDNA for PCR was optimized by the intensity of the amplified DNA products of β-actin from each RNA. In the PCR reaction mixture, either β-actin as the control primer, IL-2, IFN-γ (Clonetech, PaloAlto, Calif.), IL-4, or IL-5 at the final concentration of 0.2 μM were added. The PCR condition was as follows: 200 μM of dNTP, 10 μCi [32P]dCTP, 50 μM Tris. HCl (pH 9.0), 50 μM NaCl, 2 μM MgCl2, 0.5 mM DTT, and two units of Taq polymerase (Perkin Elmer, Branchberg, N.J.) at a final volume of 20 μl. A negative control reaction was run with each sample to verify that no PCR bands appeared in the absence of template. The optimal amplification conditions were as follows: 45 s at 94° C. for denaturation, 45 s at 67° C. for annealing, and 1 min at 72° C. for elongation and the PCR cycles were 30. The amplified DNAs of β-actin, IFN-γ, IL-2, IL-4, and IL-5 had sizes of 540, 365, 413, 354, and 349 base pairs, respectively. The gel was dried on Whatman 3M paper and exposed to Kodak XAR film. In each electrophoresis run, intra- and inter-gel staining homogeneity was confirmed by staining intensity of molecular weight markers at both ends of the gels. In general, amplification kinetics were monitored for each PCR run by examining aliquots of the products on the gel. Amounts of the PCR products were compared during the cycles where the amplification did not reach saturation.
Statistical Analysis
The immunoglobulin response data was analyzed by Student's paired t test for comparisons between control and experimental group. Histological grades were analyzed using a non-parametric Mann-Whiney U test. Data was expressed as mean±SD. A P value<0.05 was considered significant.
Results
Der p-Specific IgE, IgGI, IgG2a, and IgG Antibody Responses by Gene Vaccination.
To examine the immune response, we checked the levels of IgG, IgG1, G2a, and IgE antibody productions by ELISA (FIG. 1A-E, 2B, C, D, F). The gene vaccination with the murine T-cell epitope of Der p and 2 showed about 60% inhibition of Der p-specific IgE as compared with the control group at week 6 (FIG. 2A). Thus, genetic vaccination could inhibit an in vivo allergen-specific IgE synthesis efficiently. The production of Der p-specific IgG2a antibodies in the vaccination group was greater than that in the control group after 6 weeks (FIG. 2B). However, in the Der p-specific IgG1, and IgG responses, the two groups did not show any difference (FIGS. 2C and 2D).
Cytokine Gene Expression by Antigen Stimulation In Vivo
To determine whether the Th1 or Th2 cytokines are involved in the genetic vaccination, we performed a RT-PCR analysis on the total RNA samples extracted from lymph node cells (1×10⁷cells per well) that were cultured in the presence of Der p (100 μg/ml) in vitro for 18 hrs. A higher mRNA expression of IFN-γ in the vaccination group was detected compared with the control group. The level of mRNA expression of IL-2, 4 and 5 in the vaccination group were similar to the level in comparing of the control group (FIG. 3). These data indicate that the vaccinations with Der p epitope DNA predominantly increased Th1 cytokine (IFN-γ) gene expression in the lymph node.
Histological and Immunohistochemical Examination of Lung Tissue
To examine whether the genetic vaccination affected cellular response of lung or not, we stained the lung at the end of the experiment by histological and immunohistochemical methods. The lungs from the control group showed much more infiltration of inflammatory cells around bronchioli, blood vessels, and interstitium (table 5, FIG. 4). In the immunohistochemical stain for CD4+ and CD8+, T-cells showed that more CD8+ T-cells infiltrated in the submucosa and mucosa of the lung from the vaccination group (94.5±6.75/mm) as compared with the control group (49±4.966/mm) (FIG. 5). The stain for the CD4+ T-cells showed no difference between the two groups (vaccination group 98.5±13.44/mm versus control group 114±11.31/mm). The results suggest that the genetic vaccination also affects the cellular response, and the CD8+ T-cells of the vaccination were capable of protecting against a subsequent allergenic challenge.
Discussion
Diseases such as allergic asthma, rhinitis, and atopic dermatitis are all characterized by elevated levels of serum IgE. Total and specific IgE positivity also have showed a close relationship with clinical symptoms in atopic allergy. A variety of approaches targeting the suppression of IgE have been proposed using synthetic peptides as a T-cell vaccine. However, the synthetic peptides were poor immunogens and were needed at higher levels than the amount derived intracelluarly from processed antigens. Recently Hsu et al. showed that gene immunization of rats with plasmid encoding Der p 5 prevents induction of IgE synthesis. These data suggest that plasmid DNA (pDNA) immunization with a plasmid containing the gene for the minor HDM allergen Der p 5 may induce a Th1 immune responses to the encoded antigens. The Der p 5 allergen reacts with about 40% of allergic sera but the Der p 1 and 2 allergens react with about 80% of allergic sera.^3,5We have analyzed the effects of gene vaccination with plasmid DNA encoding only the murine T-cell epitopes in allergic responses to whole Der p extract. Our results showed about 70% inhibition of Der p-specific IgE 6 weeks after immunization with Der p (FIG. 2A).
Animal models have established that Th2 responses are mediated by T helper cells that secret cytokines such as IL-4 and IL-S that induce antibody production in B cells, including above all, the formation of IgE which plays a central role in allergic responses.^19,20IFN-γ is the Th1 cytokine responsible for the inhibition of IL-4-mediated IgE responses and promotes the formation of IgG2a.²¹Previous reports showed that protein immunization induced a Th2 response, as shown by IgG1 and IgE antibody formation and IL-4 and IL-S-secreting T-cells. In contrast, gene immunization with plasmid DNA induced a Th1 response with IgG2a antibody production and IFN-γ secreting T-cells. Our data showed that the mRNA expression of IFN-γ in lymph nodes from plasmid DNA encoding the murine T-cell epitopes of Der p 1 and 2 increased more than the expression in the control group, and this increase may be associated with suppression of IgE synthesis. In parallel, in a Th2 response, there was no difference between the two groups. Our results suggested that the genetic immunization might induce a Th1 immune response to the encoded antigen or allergen. After genetic immunization, the Th1 response dominated over the Th2 response and suppressed preexisting IgE antibody formation. Gamma interferon promotes the formation of IgG2a and inhibits IgE production¹³although the mechanism through which IFN-γ exerts its stimulatory effects on IgG2a production has not been established. Our data also showed that the production of IgG2a-anti-Der p antibody was higher in the vaccination group than the control group. Our results suggest that genetic immunization might suppress IgE production by inducing the Th1 response from T helper cells.
Allergic asthma is characterized as a chronic inflammatory disease of the bronchi and it is well established that a variety of cells including mast cells, eosinophils and lymphocytes play a role in this process. After an inhalation challenge, the inflammatory cells migrate from the peripheral blood to the site of inflammation in the bronchial mucosa and bronchoalveolar fluid and the cells predominantly express Th2-type cytokines. Our histological study showed that gene vaccination induced the reduction of infiltration of inflammatory cells in lung tissues (FIG. 4). It suggested that the change in the function of T-cells might cause a reduction of the inflammatory cells in lung tissue. These results suggested that genetic immunization affected not only humoral immune responses but also cellular responses.
T lymphocytes have been suggested to play a key role in orchestrating the interaction of the participating cells because they are able to release an array of cytokines which can attract, prime and activate other cell types. A successful outcome of immunotherapy has been associated with the development of suppressor T-cells, which can downregulate the allergic response. A recent report has also revealed that functionally distinct subsets of CD8+ T-cells may play an important regulatory role in IgE production. However, Manickan et al showed that the mechanism of genetic immunization was principally by CD4+ T-cells, but not by CD8−+-T-cells. Our immunohistochemical study showed that more CD8+ T-cells were detected in the lung of the vaccination group than that of the control group. Peptides derived from cytosolic proteins are generally presented to CD8 T-cells by major histocompatibility complex (MHC) class I molecules which are expressed on virtually all somatic cells. The results suggested that such endogenous production of an allergenic protein might be a useful means to induce regulatory CD8+ T-cells capable of conferring protection against a subsequent allergenic challenge.
The vaccination with mixed naked DNA encoding only T-cell epitopes might induce an abrogation of allergic response in mice as effectively as DNA encoding whole segment allergen. Thus genetic vaccination using DNA encoding T-cell epitopes could be an ideal way of combating allergic disease in the future.

TABLE 3

Sequence of Primers for the murine Der p1 and 2 epitopes

Der p 1 epitope (residues 21-49)	5′-CCG GAA TTC GCC GCC ACC ATG ACT GTC ACT CCC ATT CGT
	ATG C-3′
	[SEQ.ID.NO: 1]
	5′-TGC TCT AGA TTA AGC CAA ATA AGC TGA TTC AGT TGC-3′
	[SEQ.ID.NO: 2]

Der p 1 epitope (residues 78-100)	5′-CCG GAA TTC GCC GCC ACC ATG CGT GGT ATT GAA TAC ATC
	CAA CAT-3′
	[SEQ.ID.NO: 3]
	5′-TGC TCT AGA TTA TTC TCG TGC AAC GTA TCG ATA GTA-3′
	[SEQ.ID.NO: 4]

Der p 1 epitope (residues 110-131)	5′-CCG GAA TTC GCC GCC ACC ATG CGT TTC GGT ATC TCA AAC
	TAT TGC-3′
	[SEQ.ID.NO: 5]
	5′-TGC TCT AGA TTA CAA AGC TTC ACG AAT TTT GTT TGC-
	3′
	[SEQ.ID.NO: 6]

Der p 2 epitope (residues 11-35)	5′-CCG GAA TTC GCC GCC ACC ATG CAT GAA AIC AAA AAA GTT
	TTG GTA-3′
	[SEQ.ID.NO: 7]
	5′-TGC TCT AGA TTA GAA TGG TTT ACC ACG ATG AAT GAT-
	3′
	[SEQ.ID.NO: 8]

Der p 2 epitope (residues 87-129)	5′-CCG GAA TTC GCC GCC ACC ATG GAT ATT AAA TAT ACA TGG
	AAT GTT CCG A-3′
	[SEQ.ID.NO: 9]
	5′-TGC TCT AGA TTA ATC GCG GAT TTT AGC ATG AGT AGC-
	3′
	[SEQ.ID.NO: 10]

TABLE 4

Oligonucleotides used for cytokine mRNA expression

		Product
Molecules	Primer Sequence (5′ to 3′)	Size

β-actin	5′-GTG GGC CGC TCT AGG CAC CAA-3′	540 bp
	[SEQ.ID.NO: 11]
	CTC TTT GAT GTC ACG CAC GAT TTC-3′
	[SEQ.ID.NO: 12]

IL-2	5′-TTCAAGCTCCACTTCAAGCTCTACAGCGGAAG-3	413 bp
	[SEQ.ID.NO: 13]
	GACAGAAGGCTATCCATCTCCTCAGAAAGTCC-3′
	[SEQ.ID.NO: 14]

IFN-γ	5′-TGCATCTTGGCTTTGCAGCTCTTCCTCATGGC-3′	365 bp
	[SEQ.ID.NO: 15]
	TGGACCTGTGGGTTGTTGACCTCAAACTTGGC-3′
	[SEQ.ID.NO: 16]

IL-4	5′-CAG CTA GTT GTC ATC CTG CTC TTC-3′	357 bp
	[SEQ.ID.NO: 17]
	5′-GTG ATG TGG ACT TGG ACT CAT TCA TGG-3′
	[SEQ.ID.NO: 18]

IL-5	5′-TGT CTG GGC CAC TGC CAT GGA GAT TC-3′	424 bp
	[SEQ.ID.NO: 19]
	5′-CCA TTG CCC ACT CTG TACT CA TCA CAC-3′
	[SEQ.ID.NO: 20]

TABLE 5

Inflammatory cells in the lung tissue
after immunization with Der p

	Around	Around	Patch Cellular
Group	Bronchioli	blood vessels	Infiltration

Control	1.5616 ± 0.7262	1.6438 ± 1.2733	1.6471 ± 0.4926
Vaccination	0.6835 ± 0.4947*	0.3924 ± 0.5168*	0.3333 ± 0.4815*

*P < 0.05 compared with the control group

FIG. 2 a. Effect of vaccination on the allergen induced immunoglobulin E production. Blood from the 6 mice in two groups was collected three times on week 0 (first immunization), 3 and 6. The gene vaccination with the murine T-cell epitopes on Der p 1 and 2 showed about 70% inhibition of Der p-specific IgE as compared with the control mice at week 6. Data shown are mean±S.D. (n=6 per group). *P<0.05 compared with the control mice.
FIG. 2. The IgG2a (B), IgG1 (C), and IgG (C) antibody responses of BALB/c mice after immunizing with Der p extract. The production of Der p-specific IgG2a antibodies in the vaccination mice increased more than that in the control mice after 3 weeks (FIG. 2A). But in the Der p-specific IgG1 and IgG responses, there was no difference between the two groups (FIG. 2B,C). Data shown are mean±S.D. (n=6 per group). *P<0.05 compared with the control mice.
FIG. 3. Cytokine gene expression. T-cells were collected from the lymph nodes of control or vaccination mice 10 days post boost and cultured in the presence of no antigen, and Der p extract (100 μg/ml) for 18 hrs. The total RNA was extracted using TRIzol reagent and RT-PCR reactions was done using cDNA with different primers specific for β-actin, IL-2, 4, 5, and interferon-γ. 1) Lymph node cells from control mice were cultured without Der p 2) in the presence of Der p (100 μg/ml), 3) Lymph node cells from vaccinated mice were cultured without Der p, and 4) in the presence of Der p (100 μg/ml). A higher mRNA expression of IFN-γ in the vaccination group was detected compared with the control group.
FIG. 4. Histopathologic examination of lung. Lungs from control and experimental groups of mice were removed on day 45 after immunization. (A) Lung from control mouse (×100). (B) Lung from control mouse (×400). (C) lung from vaccination mouse (×100). (D) Lung from vaccination mouse (×400). Vaccination mice showed much less the infiltration of inflammatory cells than control mice.
FIG. 5. Immunohistochemical examination of lung. Lungs from control and vaccination group were removed on day 45 after immunization and were stained for CD8+ T-cells. (A) Lung from control mouse (×100). (B) Lung from vaccination mouse (×100). More CD8+ T-cells were observed in vaccination mice in comparing with control mice.

Example 3

Suppressive Effect on the Allergen-Induced Immunoglobulin E Production by the Naked DNA

We have investigated immune responses resulting from gene immunization with plasmid DNA encoding major HDM allergen ( Der p 1, 2, 3, Der f 1, 2, and 3) followed by challenges with whole HDM crude extract in mice to mimic a realistic clinical setting. We have demonstrated that gene vaccination indeed induced strong Th1 immune responses, which reduced the IgB antibody production and allergic responses against HDM.
Methods
Mice
20 BALB/c mice at the age of 6-8 weeks were purchased from Jackson Laboratory (Bar Harbor, Me.) and bred at the University of Tennessee (Memphis, Tenn.) This study was performed in accordance with the PHS Policy on Humane Care and Use of Laboratory Animals, the NIH Guide for the Care and Use of Laboratory Animal Welfare Act (7 U.S.C. et seq.); the animal use protocol was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Tennessee.
Plasmid Construction
Total mRNA was isolated from Der p and Der f HDM, respectively. By using murine leukemia virus reverse transcriptase and random hexanucleotide primers following the instructions of the Perkin Elmer Gene Amp RNA PCR kit (Perkin Elmer, Branchberg, N.J.), first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR. The cDNA was used in PCR with Taq polymerase and primers specific for Der p 1-3 and Der f 1-3. These primers, which cover the mature excreted region of each gene and include EcoR1 and Xba1 sites for cloning are summarized in Table 1. The amplified PCR products were subcloned into pcDNA3.1 eukyrotic expression vector (Invitrogen, San Diego, Calif.) and then sequenced.
DNA Preparation and Vaccination
Each plasmid construct was prepared using Maxi prep (Qiagen, Chatsworth, Calif.). Mice were vaccinated by injection with 300 μg of pcDNA3.1 blank vector in 100 μl of PBS (control group) or with 300 μg of the mixed naked DNA encoding the major HDM allergens in 100 μl of PBS (vaccination group) three times at weekly intervals into muscle ( week 0, 1 and 2). To verify expression, mRNA was prepared from muscle of the injected mice, and used for RT-PCR. We found PCR products of HDM major allergen genes from experimental group mice (data not shown).
Immunization and Inhalation of Allergen to Mice
HDM crude extracts (Der p and Der 1) were dialyzed, concentrated, and dissolved in PBS buffer. HDM allergen was emulsified with an equal volume of complete Freund's adjuvant (CFA) for immunization. Three weeks after the last vaccination, mice were sensitized subcutaneously at the base of the tail with 100 μg of HDM extract in CFA (week 5). The mice were also given an intraperitoneal dose of 300 ng of purified pertussis toxin at 24 and 72 hours after first immunization. Seven days later, the mice were boosted again with the same amount of antigen in incomplete Freund's adjuvant (week 6). Mice were treated by intranasal administration with 10 μg of HDM crude extract six times at weekly intervals from boost (week 6 to 11).
Expression and Purification of Recombinant Der p 1 Peptide
Recombinant Der p 1 peptide was generated to use as an antigen. The Der p 1 gene were amplified by RT PCR with primers specific for Der p 1 (5′-CCG GAA TTC ATG GAA ACT AAC GCC TGC AGT-3′ [SEQ. ID. NO:55] and 5′-TGC TCT AGA TTA GAG AAT GAC AAC ATA TGG ATA TTC-3′[SEQ. ID. NO:56]) and subcloned into pMAL-c2 (NEB, Beverly, Mass.), prokaryotic expression vector, using EcoR1 and Xba1 sites. Recombinant Der p 1 was expressed in E. coli by induction with IPTG at an O.D.₆₀₀of 0.5 in liquid culture for 4 h at 37° C. The purification of fusion proteins was performed with amylose resin (NEB, Beverly, Mass.). Fractions containing recombinant Der p 1 of >95% purity were dialyzed against 1×PBS buffer and lyophilized until use.
Determination of IgE and HDM Specific IgG
Blood from the 6 mice in two groups was collected six times on week 0 (first vaccination), 3, 5 (first immunization), 7, 9, and 11. The HDM specific IgG levels were determined by ELISA as follows. One hundred microliters of HDM (5 μg/ml in 0.1 M carbonate buffer, pH 9.6) were dispensed in each well of a polystyrene microtiter plate (Cost, Cambridge, Mass.) and incubated overnight at 4° C. The antigen-coated plates were washed three times in 0.05% PBS-Tween 20 buffer (washing buffer) and incubated with mice sera overnight at 4° C. The plates were washed five times with washing buffer and incubated with peroxidase conjugated anti-mouse IgG antibody (Sigma, St. Louis, Mo.) overnight at 4° C. The plates were washed five times before adding citric acid-phosphate buffer (pH 5.0) containing 0.15 mg/ml of O-phenylenediamine (Sigma, St. Louis, Mo.). The color was developed at room temperature, and the reaction was stopped by 2.5 M sulfuric acid. The color was measured at 492 nm (Bio-Rad, Richmond, Calif.). The total IgE level was determined by ELISA as follows. One hundred microliter of anti-mouse IgE capture mAb (clone R35-72; Pharmingen, San Diego, Calif.) were added in each well to plate and incubated overnight at 4° C. After washing, two hundred microliters of 10% fetal calf serum were incubated at room temperature for 30 min. The plates were washed five times with washing buffer and incubated with the diluted mouse serum overnight at 4° C., followed by the addition of one hundred microliter of HRP-conjugated anti-mouse IgE detection mAb (clone R35-118; Pharmingen, San Diego, Calif.) overnight at 4° C. After washing, color was developed by the same procedure as the IgG level determination. The purified mouse serum (Pharmigen, San Diego, Calif.) was used for the total IgE standard. In order to measure the HDM specific IgE, the plates were coated with 25 μg/ml HDM in 0.1 M carbonate buffer (pH 9.6) and serum samples were diluted fivefold in 10% FCS. The other procedures were the same as for the measurement of HDM-specific IgG. The level of HDM-specific IgE was referenced to the standard serum pooled from six mice that were immunized with 100 μg of HDM twice and inhaled with 10 μg of antigen six times. The standard serum was calculated as 100 ELISA units/ml.
Immunohistochemical Staining for CD4+ and CD8+ T-Cells in Lung.
The lung tissues from the experimental and control group mice were removed after the final intranasal inhalation. The tissues were fixed with periodate-lysine-paraformaldehyde solution for 24 h at 4° C. The specimens were rinsed with 0.01 M of PBS (pH 7.4), containing 10% to 20% sucrose, for 36 h at 4° C., embedded in OCT compound (Miles Laboratories Inc., Elkhart, Ind.), and immediately frozen. The lung specimen was immersed into 10% EDTA and decalcified for ten days at 4° C. Frozen sections cut at 4 to 6 μm in thickness were dehydrated and rinsed in cold PBS. The endogenous pseudoperoxidase was blocked with absolute methanol containing 0.5% hydrogen peroxide for 20 min at room temperature. The sections were treated with 10% normal goat serum in PBS to reduce the nonspecific binding. Biotin conjugated rat anti-mouse CD8 or CD4 monoclonal antibody (Pharmingen, San Diego, Calif.) diluted to 1:200 in PBS containing 0.5% bovine serum albumin was applied to the sections and incubated overnight at 4° C. After rinsing, the sections were incubated with avidin-biotin peroxidase complexes (Vectastain Elite ABC Kit, Vector Laboratories Inc., Burlingame, Calif.) for 30 min at room temperature and rinsed sufficiently with PBS. The reaction was developed with 0.02% 3,3′-diaminobenzidine in 0.05 M of Tris buffer (pH 7.6) with 0.005% hydrogen peroxidase for 7 min. The sections were dehydrated, cleared in xylene, and mounted.

Histological Examination of Lung Tissue

Mice were anesthetized with a mixture of ketalar (35 mg/ml), rompun (0.6%/ml) and atropine (0.1 mg/ml) of which 0.2 ml was injected intramuscularly. The vascular bed of the lungs was perfused with 0.01 M Phosphate-buffered saline (PBS) and then with 4% paraformaldehyde 0.1 M PBS buffers. Whole lungs were taken out and were stored in 4% paraformaldehyde for 24 h at 4° C. After fixation, these tissues were dehydrated and embedded in paraffin. Frozen sections cut at 3 μm in thickness were stained by hematoxylin and eosin. After coding, the sections were evaluated by two observers using light microscopy. The amount of inflammatory cells per section was scored using the method described by Mehlhop et al. Lungs that showed no local inflammation were scored as grade 0. Those that showed one or two centrally located microscopic foci of inflammatory infiltrate were graded as 1. In grade 2, a dense inflammatory infiltrate was seen in a perivascular and peribronchial distribution originating in the center of the lung. In grade 3, the perivascular and peribronchial infiltrates extended to the periphery of the lung.
Measuring Cytokine mRNA Expression
Mice from two groups were sacrificed 10 days postboots. The lymph nodes were removed from mice and stimulated with recombinant Der p 1 (100 μg/ml) or HDM crude extract (100 μg/ml) in vitro for 18 hrs. The cells were washed with PBS buffer and mRNAs prepared (Biotecx, Houston, Tex.). By using murine leukemia virus reverse transcriptase and random hexanucleotide primer following the instructions of the Perkin Elmer Gene Amp RNA PCR kit (Perkin Elmer, Branchberg, N.J.), first-strand cDNA was generated from 1 μg of total RNA and subjected to RT-PCR analysis. To determine the relative abundance of each cytokine mRNA expression, the amount of each cDNA for PCR was optimized by the intensity of the amplified DNA products of β-actin from each RNA. In the PCR reaction mixture, either β-actin as control primer, IL-2, IFN-γ (Clonetech, PaloAlto, Calif.), IL-4, IL-5, IL-10 at the final concentration of 0.2 μM was added. The PCR condition was as follows: 200 μM of dNTP, 10 μCi [32P]dCTP, 50 μM Tris HCl (pH 9.0), 50 μM NaCl, 2 μM MgCl₂, 0.5 mM DTT, and two units of Taq polymerase (Perkin Elmer, Branchberg, N.J.) at a final volume of 20 μl. A negative control reaction was run with each sample to verify that no PCR bands appeared in the absence of template. The optimal amplification conditions were as follows: 45 s at 94° C. for denaturation, 45 s at 67° C. for annealing, and 1 min at 72° C. for elongation and the PCR cycles were 30. The amplified DNAs of β-actin, IFN-γ, IL-2, IL-4, IL-5, and IL-10 had sizes of 540, 365, 413, 354, 349, and 455 base-pairs, respectively. The gel was dried on Whatman 3M paper and exposed to Kodak XAR film. In each electrophoresis run, intra- and inter-gel staining homogeneity was confirmed by staining intensity of molecular weight markers at both ends of the gels. In general, amplification kinetics were monitored for each PCR run by examining aliquots of the products on the gel. Amounts of the PCR products were compared during the cycles where the amplification did not reach saturation.
Statistical Analysis
Immunoglobulin response data were analyzed by Student's paired t test for comparisons between the control and experimental group. Histological grades were analyzed using a non-parametric Wilcoxon test. Data was expressed as mean±SD. A P value<0.05 was considered significant.
Results
Downregulation of Der p-specific IgE antibody production by gene vaccination.
To examine the immune response, we checked levels of the IgG and IgE antibody productions by ELISA (FIG. 3). The gene vaccination with the major HDM allergen genes, Der p 1, 2, 3, Der f 1, 2, and 3, showed about 70% inhibition of HDM-specific IgE and more than 70% inhibition of total IgE as compared with the control group after 6 weeks immunization. Thus, genetic vaccination could inhibit an in vivo allergen-specific IgE synthesis efficiently even though HDM-specific IgG antibody production of both groups were at almost the same level (FIG. 3C).
Histological and Immunohistochemical Study
To examine whether the genetic vaccination has an affect on the cellular response of lung or not, we stained the lung at the end of the experiment by histological and immunohistochemical methods. The lungs from the control group (mean grade 1.64±0.52) showed much greater infiltration of inflammatory cells in the submucosa of airways than that of the vaccination group (mean grade 0.68±0.48). Eosinophils were also detected in the lungs of the control mice (FIGS. 4 and 5). In the immunohistochemical stain for CD4+ and CD8+, T-cells showed that more CD8+ T-cells infiltrated the submucosa and mucosa of the airway of the lung from the vaccination group as compared with the control group (FIGS. 4 and 5). However, in the stain for the CD4+ T-cells showed no difference between the two groups. The results suggested that the genetic vaccination also affect the cellular response and the CD8, T-cells of the vaccination were capable of protecting against a subsequent allergenic challenge.
Cytokine Gene Expression by Antigen Stimulation In Vivo
To determine whether the Th1 or Th2 cytokines are involved in the effect of genetic vaccination, T-cells were harvested from lymph nodes of the two groups of mice and stimulated with recombinant Der p 1 or HDM crude extract in vivo. A higher mRNA expression of IFN-γ in the vaccination group was detected compared with the control group. However in the mRNA expression of IL-2, 4, 5, and 10 of both groups were similar. These data indicate that the vaccinations with HDM major genes induced a strong Th1 cytokine (IFN-γ) gene expression in the lymph node.
Discussion
Diseases such as allergic asthma, rhinitis, and atopic dermatitis are all characterized by elevated levels of serum IgE. Total and specific IgE positivity also showed a close relationship with clinical symptoms of atopic allergy.¹⁵A variety of approaches targeting the suppression of IgE have been proposed using synthetic peptides as a T-cell vaccine. However, the synthetic peptides were poor immunogens and were needed at higher levels than the amount derived intracelluarly from processed antigens. Recently Hsu et al.¹⁰showed that gene immunization of rats with plasmid encoding Der p 5 prevent induction of IgE synthesis. These data suggest that pDNA immunization with a plasmid containing the gene for the minor HDM allergen Der p 5 may induce Th1 immune responses to the encoded antigens. The Der p 5 allergen reacts with about only 40% of allergic sera, but the Der p 1 and 2 allergens react with about 80% of allergic sera. We have analyzed the effects of gene vaccination with plasmid encoding major 6 HDM allergens ( Der p 1, 2, and 3, Der f 1, 2, and 3) in allergic responses to whole HDM crude extract. Our results showed about 50% inhibition of HDM-specific IgE and more than 70% inhibition of total IgE at week at the end of the study (FIGS. 3 a and b). Thus, this result suggested that gene immunization with a plasmid encoding the major HDM antigen can also induced inhibition of IgE synthesis. Animal models have established that Th2 responses are mediated by T helper cells that secret cytokines such as IL-4, IL-5 and IL-10 that induce antibody production in B cells, including above all, the formation of IgE which plays a central role in allergic responses. IFN-γ is the Th1 cytokine responsible for the inhibition of IL-4-mediated IgE responses and promotes the formation of IgG2a. Previous reports showed that protein immunization induced a TH2 response, as shown by IgG1 and IgE antibody formation and IL-4 and IL-5-secreting T-cells. In contrast, gene immunization with plasmid DNA induced a Th1 response with IgG2a antibody production and IFN-γ secreting T-cells. Genetic vaccination in many infectious disease, and allergic disease have an enhanced Th1 response for preventing several diseases. Our gene vaccination data showed that the mRNA expression of IFN-γ in the lymph node from pDNA encoding the HDM allergens Der p 1, 2, 3, &and Der f 1, 2, 3 gene increased more than that from the control group. This data suggested that the genetic immunization might induce Th1 immune response to the encoded antigen or allergen. After genetic immunization, the Th1 response dominated over the TH2 response and downregulates preexisting IgE antibody formation. Our experiment suggested that genetic immunization might suppress IgE production by the inducing the TH1 response from T helper cells.
Allergic asthma is characterized as a chronic inflammatory disease of the bronchi and it is well established that a variety of cells including mast cells, eosinophils and lymphocytes play a role in this process. After an inhalation challenge, the inflammatory cells migrate from the peripheral blood to the site of inflammation in the bronchial mucosa and bronchoalveolar fluid expressing predominantly Th2-type cytokines. Our histological study showed that gene vaccination induced the reduction of infiltration of inflammatory cells in lung tissues (FIG. 4). This result suggested that the change in the function of T-cells might cause the reduction of the inflammatory cells in bronchial mucosa. This data indicated that gene immunization affects not only humoal immune responses but also cellular responses. T lymphocytes have been suggested to play a key role in orchestrating the interaction of the participating cells since they are able to release an array of cytokines which can attract, prime and activate other cell types. A successful outcome of immunotherapy has been associated with the development of suppressor T-cells, which can downregulate the allergic response. Recent data have also revealed that functionally distinct subsets of CD8+ T-cells may play an important regulatory role in IgE production. However, Manickan et al. showed that the mechanism of genetic immunization was principally by CD4+ T-cells, and not by CD8+ T-cells. Recently Lee et al. reported that both CD4+ and CD8+ subsets of T-cells from mice immunized with plasmid DNA can suppress IgE antibody production by affecting the primary response and/or by propagating the Th1 memory response in a passive cell transfer system. Our immunohistochemical study showed that more CD8+ T-cells were detected in the lung of the vaccinated group than that of the control group (FIG. 5). Peptides derived from extracellular molecules are presented to CD4+ T-cells by MHC class II molecules normally generated by antigen-presenting cells,³⁶whereas peptides derived from cytosolic proteins are generally presented to CD8+ T-cells by major histocompatibility complex (MHC) class I molecules which are expressed on virtually all somatic cells. We injected the mixed naked DNA into muscle of BALB/c mice. Our Results suggested that such endogenous production of an allergenic protein might be a useful means to induce regulatory CD8+ T-cells capable of conferring protection against a subsequent allergenic challenge. Our represented results here showed that vaccination with plasmid DNA encoding specific allergen genes in an animal model provided an efficient clinical method for modulation allergic responses.

TABLE 6

Oligonucleotides used for Der p1-3 and Der f 1-3 in this study

Molecule
Primer	Sequence (5′ to 3′)

Der p 1	5′-CCG GAA TTC GCC GCC ACC ATG GAA ACT AAC GCC TGC AGT ATC AAT
	GGA-3′
	[SEQ.ID.NO: 21]
	5′-TGC TCT AGA TTA GAG AAT GAC AAC ATA TGG ATA TTC-3′
	[SEQ.ID.NO: 22]

Der p 2	5′-CCG GAA TTC GCC GCC ACC ATG GAT CAA GTC GAT GTC
	AAA GAT TGT GCC-3′
	[SEQ.ID.NO: 23]
	5′-TGC TCT AGA TTA ATC GCG GAT TTT AGC ATG AGT AGC AAT-3′
	[SEQ.ID.NO: 24]

Der p 3	5′-CCG GAA TTC GCC GCC ACC ATG ATT GTT GGT GGT GAA AAA GCA TTA
	GCTG-3′
	[SEQ.ID.NO: 25]
	5′-TGC TCT AGA TTA CTG TGA ACG TTT TGA TTC AAT CCA ATC GATA-
	3′
	[SEQ.ID.NO: 26]

Der f 1	5′-CCG GAA TTC GCC GCC ACC ATG GAA ACA AGC GCT TGC CGT ATC AAT
	TCG-3′
	[SEQ.ID.NO: 27]
	5′-TGC TCT AGA TTA GAG GTT GTT TCC GGC TTG GAA ATA TCC G-3′
	[SEQ.ID.NO: 28]

Der f 2	5′-CCG GAA TTC GCC GCC ACC ATG GAT CAAA GTC GAT GTT AAA GAT TGT
	GCC-3′
	[SEQ.ID.NO: 29]
	5′-TGC TCT AGA TTA ATC ACG GAT TTT ACC ATG GGT AGC AAT-3′
	[SEQ.ID.NO: 30]

Der f 3	5′-CCG GAA TTC GCC GCC ACC ATG ATT GTT GGT GGT GTG AAA GCA CAA
	GCC-3′
	[SEQ.ID.NO: 31]
	5′-TGC TCT AGA TTA CTG TGA ACG TTT TGA TTC AAT CCA ATC GAC-3′
	[SEQ.ID.NO: 32]

TABLE 7

Oligonucleotides used for cytokine mRNA expression in
this study

		Product
Molecules	Primer Sequence (5′ to 3′)	Size

β-actin	5′-GTG GGC CGC TCT AGG CAC CAA-3′	540 bp
	SEQ.ID.NO: 33]
	5′-CTC TTT GAT GTC ACG CAC GAT TTC-3′
	[SEQ.ID.NO: 34]

IL-2	5′-TTCAAGCTCCACTTCAAGCTCTACAGCGGAAG-3′	413 bp
	[SEQ.ID.NO: 35]
	5′-GACAGAAGGCTATCCATCTCCTCAGAAAGTCC-3′
	[SEQ.ID.NO: 36]

IFN-γ	5′-TGCATCTTGGCTTTGCAGCTCTTCCTCATGGC-3′	365 bp
	[SEQ.ID.NO: 37]
	5′-TGGACCTGTGGGTTGTTGACCTCAAACTTGGC-3′
	[SEQ.ID.NO: 38]

IL-4	5′-CAG CTA GTT GTC ATC CTG CTC TTC-3′	357 bp
	[SEQ.ID.NO: 39]
	5′-GTG ATG TGG ACT TGG ACT CAT TCA TGG-3′
	[SEQ.ID.NO: 40]

IL-5	5′-TGT CTG GGC CAC TGC CAT GGA GAT TC-3′	424 bp
	[SEQ.ID.NO: 41]
	5′-CCA TTG CCC ACT CTG TACT CA TCA CAC-3′
	[SEQ.ID.NO: 42]

IL-10	5′-ATG CAG GAC TTT AAG GGT TACT TG GGT-3′	455 bp
	SEQ.ID.NO: 43]
	5′-ATT TCG GAG AGA GGT ACA AAC GAG G-3′
	[SEQ.ID.NO: 44]

Figure Legend
FIG. 3. Effect of vaccination on the allergen induced immunoglobulin production. The total IgE antibody response (A), and the HDM-specific IgE antibody response (B), and changes of HDM-specific IgG antibody respons (C), of BALB/c mice after immunization of whole HDM crude extract. Data shown are means±SD (n=6 per group). *P<0.05 compared with the control group.
FIG. 4. Histopathologic Examination of Lung.
Lungs from control and experimental groups of mice were removed on day 45 after immunization. (A) Lung from control mouse (×100). (B) Lung from control mouse (×200). (C) Lung from vaccination mouse (×200). (D) Bronchial wall from control mouse (×600). Eosinophils and many inflammatory cells were observed in control group. Vaccination mice showed much less infiltration of inflammatory cells than control mice.
FIG. 5. Immunohistochemical Examination of Lung.
Lungs from control and vaccination group were removed on day 45 after immunization and were stained for CD8+ T-cells. (A) Lung from control mouse (×100). (8) Lung from vaccination mouse (×100). (C) Lung from control mouse (×200). (D) Lung from vaccination mouse (×200). (E). Bronchial wall from vaccination mouse (×400). More CD8+ T-cells were observed in vaccination mouse.
T-cells were collected from the lymph nodes of control or vaccination mice 10 days post boost and cultured in the presence of no antigen(−), recombinant Der p 1 (100 μg/ml), and HDM crude extract (100 μg/ml) for 18 h. The total RNA was extracted using TRIzol reagent and RT-PCR reactions were doing using cDNA with different primers specific for β-actin, IL-2, 4, 5, 10 and interferon-y.
Although only a few exemplary embodiments of this invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the following claims.

1. Platts-Mills, T. A. E., and Chapman. M. D., Dust mites: immunology, allergic disease, and environmental control. J. Allergy Clin. Immunol. 1987; 80:755-75.
2. International workshop report. Dust mite allergens and asthma: a world wide problem. WHO Bulletin 1988; 66:769-80.
3. Ulmer, J. B., Donnelly, J. J, Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., Hawe, L. A., Leander, K. R., Martinez, D., Perry, H. C., Shiver, J. W., Montgomery, D. L., and Liu, M. A., Heterologous protection against influenza by infection of DNA encoding a viral protein. Science 1993; 259:1745-49.
4. Wang, B., Ugen, K. E., Srikantan, V., Agadjanyan, M. G., Dang, K., Refaeli, Y., Sato, A. I., Boyer, J., Williams, W. V., and Weiner, D. B., Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 1993; 90:4156-60.
5. Raz, E., Carson, D. A., Parker, S. E., Par, T. B., Abai, A. M., Aichinger, G., Gromkowski, S. H., Lew, D., Uankauckas, M. A., Baird, S. M., and Rhodes, G H., Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses. Proc. Natl. Acad. Sci. USA 1994; 91:9519-23.
6. Wolff, J. A., Ludtke, J. J., Acsadi, G., Williams, P., and Jani, A, Long persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum. Mol. Gen. 1992; 1:363-39.
7. Hsu, C. H., Chua, K. Y., Tao, M. H., Lai, Y. L., Wu, H. D., Huang, S. K., and Hsieh, K. H., Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vitro by genetic immunization. Nature Med. 1996; 2:540-44.
8. Slater, J. E., Zhang, Y. J., Arthur-Smith, A. A., Colberg-Poley, A. A., DNA vaccine inhibits IgE responses to the latex allergen Hev b 5 in mice. J. Allergy Clin. Immunol. 1997; 99:s504.
9. Broide, D., Orozco, E. M., Roman, M., Carton, D. A., and Raz, E., Intradermal gene vaccination down-regulates both arms of the allergic response. J. Allergy Clin. Immunol. 1997; 99:s 129.
10. Raz, E., Tighe, H., Sato, Y., Corr, M. P., Dudler, J. A., Roman, M., Swain, S. L., Spiegelberg, H. L., and Carson, D. A., Preferential induction of a TH1 response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. U.S.A. 1996; 93:5141-45.
11. Cheng, K. C., Lee, K. M., Krug, M. S., Watanabe, T., Suzuki, M., Choe, I. S., and Yoo, T. J., House dust mite-induced sensitivity in mice. J. Allergy Clin. Immunol. 1998; 101:51-59.
12. Enander, I., Ahlstedt, S., and Nygren, H., Mononuclear cells, mast cells and mucous cells as part of the delayed hypersensitivity response to aerosolized antigen in mice. Immunol. 1984; 51:661-68.
13. Hessel, E. M., Van Oosterhout, A. J. M., Hofstra, C. L., De Bie, J. J., Garssen, J., Van Loveren, H., Verheyen, A. K. C. P., Savelkoul, H. F. J., and Nijkamp, F. P., Bronchoconstriction and airway hyperresponsiveness after ovalbumin inhalation in sensitized mice. European Journal of Phamacology Environmental Toxicology and Phamacology 1995; Section 293:401-12.
14. Droste, J. H., Kerkhof, M., de Monchy, Jan G. R., Schouten, Jan P., Rijcken, B., and Dutch ECRHS group: Association of skin test reactivity, specific IgE, total IgE, and eosinophils with nasal symptoms in a community-based population study. J. Allergy Clin. Immunol. 1996; 97:922-32.
15. Yssel, H., Johnson, K. E., Schneider, P. V., Wideman, J., Terr, A., Kastecin, R., and de Vries, J. E, activation-inducing epitopes of the house dust mite allergen Der p 1. Proliferation and lymphokine production patterns by Der p 1-specific CD+4 T-cell clones. J. Immunol. 1992; 148, 738-45.
16. Higgins, J. A., Lamb, J. R., March, S. G. E., Hayball, J. D., Rosen-Bronson, S., Bodmer, J. G., and O'Hehir, R. E., Peptide-induced nonresponsiveness of HLA-DP restricted human T-cells reactive with Dermatophagoides spp. (house dust mite). J. Allergey Clin Immunol. 1992; 90:749-56.
17. Bot, A., Rot, S., Karjalainen, K., and Bona, C., Kinetics of generation and persistence on membrane class II molecules of a viral peptide expressed on foreign and self proteins. J. Immunol. 1996; 157(8):3436-42.
18. Demotz, S., Grey, H. M., and Sette, A., The minimal number of class II MHC-antigen complexes needed for T-cell activation. Science 1990; 249(4972): 1028-30.
19. Van der Zee, J. S., Van Swieten, P., Janse, H. M., and Aalberse, R C., Skin tests and histamine release with P1-depleted Dermatophagoides pteronyssinus body extracts and purified P1. J. Allergy Clin. Immunol. 1988; 81:884-951.
20. Lin, K. L., Hsieh, K. H., Thomas, W. R., Chiang, B. L., and Chua, K Y., Allergens, IgE, Mediators, inflammatory mechanisms. Characterization of Der p 5 allergen, cDNA analysis, and IgE-mediated reactivity to the recombinant protein. J. Allergy Clin. Immunol. 1994; 94:989-96.
21. Singer, G. G., and Abbas, A. K., The Fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T-cell receptor transgenic mice. Immunity 1994; 1:365-71.
22. Chen, Y., Inobe, J., Marks, R., Gonnella, P., Kuchroo, V. K., and Weiner, H. L., Peripheral deletion of antigen-reactive T-cells in oral tolerance. Nature 1995; 376: 177-80.
23. Tighe, H., Corr, M., Roman, M., and Raz, E., Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 1998; 19(2):89-97.
24. Mosmann, T. R., and Coffman, R. L., TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 1989; 7:145-73.
25. Finkelman, F. D., Katona, I. M., Urban, J. F. Jr., Holmes, J., Ohara, J., Tung, A. S., Sample, J. V. G., and Paul, W. E., IL-4 required to generate and sustain in vivo IgE responses. J. Immunol, 1988; 141:2335-41.
26. Snapper, C. M., and Paul, W. E., Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987; 236:944-47.
27. Lee D. J., Tighe, H., Corr, J. A., Roman, M., Carson, D. A., Spiegelberg, H. L., and Raz, E., Inhibition of IgE antibody formation by plasmid DNA immunization is mediated by both CD4+ and CD8+ T-cells. Int. Arch. Allergy Immunol. 1997; 113:227-30.
28. Coffman, R. L., Ohara, J., Bond, M. W., Carty, J., Zlotnik, A. and Paul, W. E., B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J. Immunol. 1986; 136(12):4538-41.
29. Krug N., Tshernig, T., Holgate, S., and Pabst, R., How do lymphocytes get into the asthmatic airways? Lymphocyte traffic into and within the lung in asthma. Clini. Experi. Allergy 1998; 28:10-18.
30. Ying, S., Durham, S. R., Cirrogan, C. J., Hamid, Q., and Kay, A. B., Phenotype of cells expressing mRNA for Th2-type (interleukin 4 and interleukin 5) and Th1-type (interleukin 2 and interferon) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am. J. Respir. Cell Mol. Biol. 1995; 12:477-87.
31. Humbert, M., Durham, S. R., Ying, S., Kimmitt, P., Barkans, J., Assoufi, B., Pfister. R., Menz, G., Robinson, D. S., Kay, A. B., and Corrigan, C. J., IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthama: evidence against ‘intrinsic’ asthma being a distinct immunopathologic entity. Am, J. Respir, Crit, Care Med, 1996; 154:1497-504.
32. Hsieh, K. H, Changes of lymphoproliferative responses of T-cell subsets to allergen and mitogen after hyposensitization in asthmatic children. J. Allergy Clin Immunol. 1984; 74:34-40.
33. Hsich, K. H. Lue, K. H., and Chiang, C. F., Immunological changes after hyposensitization in house-dust-sensitive asthmatic children. J. Asthma 1987; 24:19-27.
34. Mehlhop et al., A murine model of allergic rhinitis: studies on the role of IgE in pathogenesis and analysis of the eosinophil influx elicited by allergen and eotaxin. J. Allergy Clin. Immunol. 1998; 102(1):65-74
35. Manickan et al., Genetic immunization again s herpes simplex virus: Protection is mediated by CD4+ T lymphocytes. J. Immunol. 1995; 155:259-265.

Claims

1. A composition comprising a mixture of naked DNA comprising nucleic acid sequences encoding portions of dust mite antigens amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46 for Der p 1, SEQ ID NO:47 and SEQ ID NO:48 for Der p 1, SEQ ID NO:49 and SEQ ID NO:50 for Der p 2, SEQ ID NO: 51 and SEQ ID NO:52 for Der p 2, SEQ ID NO: 53 and SEQ ID NO:54 for Der p 2, SEQ ID NO:1 and SEQ ID NO:2 for Der p 1, SEQ ID NO:3 and SEQ ID NO:4 for Der p 1, SEQ ID NO:5 and SEQ ID NO:6 for Der p 1, SEQ ID NO:7 and SEQ ID NO:8 for Der p 2, SEQ ID NO:9 and SEQ ID NO:10 for Der p 2, SEQ ID NO:21 and SEQ ID NO:22 for Der p 1, SEQ ID NO:23 and SEQ ID NO:24 for Der p 2, SEQ ID NO:25 and SEQ ID NO:26 for Der p 3, SEQ ID NO:27 and SEQ ID NO:28 for Der f 1, SEQ ID NO:29 and SEQ ID NO:30 for Der f 2, and SEQ ID NO:31 and SEQ ID NO:32 for Der f 3.

2. The composition of claim 1, wherein each of said sequences is on separate naked DNA.

3. The composition of claim 1, wherein said composition is administered to a mammal.

4. The composition of claim 1, wherein said composition is administered to a human.

5. A method comprising administering to a human, a composition comprising a pharmaceutically acceptable carrier and a mixture of naked DNA comprising sequences encoding portions of immunogenic dust mite antigens amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46 for Der p 1, SEQ ID NO:47 and SEQ ID NO:48 for Der p 1, SEQ ID NO:49 and SEQ ID NO:50 for Der p 2, SEQ ID NO: 51 and SEQ ID NO:52 for Der p 2, SEQ ID NO: 53 and SEQ ID NO:54 for Der p 2, SEQ ID NO:1 and SEQ ID NO:2 for Der p 1, SEQ ID NO:3 and SEQ ID NO:4 for Der p 1, SEQ ID NO:5 and SEQ ID NO:6 for Der p 1, SEQ ID NO:7 and SEQ ID NO:8 for Der p 2, SEQ ID NO:9 and SEQ ID NO:10 for Der p 2, SEQ ID NO:21 and SEQ ID NO:22 for Der p 1, SEQ ID NO:23 and SEQ ID NO:24 for Der p 2, SEQ ID NO:25 and SEQ ID NO:26 for Der p 3, SEQ ID NO:27 and SEQ ID NO:28 for Der f 1, SEQ ID NO:29 and SEQ ID NO:30 for Der f 2, and SEQ ID NO:31 and SEQ ID NO:32 for Der f 3.

6. The composition of claim 1, wherein the DNA is plasmid DNA.

7. The composition of claim 1, wherein at least one portion of an immunogenic dust mite antigen is from Der p 1 and another portion of an immunogenic dust mite antigen is from Der p 2.

8. The composition of claim 1, wherein the naked DNA is a plasmid comprising a promoter/enhancer transcriptionally linked to said portions of dust mite antigens.

9. The method of claim 5, wherein the DNA is plasmid DNA.

10. The method of claim 5, wherein said administering comprises one or more methods selected from the group consisting essentially of intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection.

11. The method of claim 5, wherein each of said sequences is on separate naked DNA.

12. The method of claim 5, wherein the composition is administered to a human having an allergic reaction to dust mites.

13. The method of claim 5, wherein administering suppresses IgE antibody production in said human.

14. The method of claim 5, wherein administering increases interferon-γ expression in said human.

15. The method of claim 5, wherein administering induces Th1 immune response in said human.

16. The method of claim 5, wherein the naked DNA is a plasmid comprising a promoter/enhancer transcriptionally linked to said portions of dust mite antigens.

17. The method of claim 5, wherein said method comprises administering said naked DNA with a transfection facilitating material.

18. The method of claim 5, wherein the composition comprises at least one portion of an immunogenic dust mite antigen is from Der p 1 and another portion of an immunogenic dust mite antigen is from Der p 2.

19. The method of claim 5, wherein said portions of immunogenic dust mite antigens are portions of Der p 1 amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:45 and SEQ ID NO:46, SEQ ID NO:47 and SEQ ID NO:48, SEQ ID NO:1 and SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, and SEQ ID NO:21 and SEQ ID NO:22.

20. The method of claim 5, wherein said portions of immunogenic dust mite antigens are portions of Der p 2 amplified by two or more primer pairs selected from the group consisting of SEQ ID NO:49 and SEQ ID NO:50, SEQ ID NO: 51 and SEQ ID NO:52, SEQ ID NO: 53 and SEQ ID NO:54, SEQ ID NO:7 and SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10, and SEQ ID NO:23 and SEQ ID NO:24.